Can I Take Glutathione with Fosamax (Alendronate)?

Direct answer

There is no documented pharmacokinetic or pharmacodynamic interaction between glutathione and alendronate (Fosamax), an oral bisphosphonate used for osteoporosis and Paget's disease of bone. The practical concern is not a drug-supplement clash but timing: alendronate has extremely poor and fragile oral absorption, and taking any oral supplement, including glutathione, too close to a dose can reduce how much of the drug the body actually absorbs. Separating oral glutathione from alendronate by at least two hours removes most of the plausible risk. This guidance has not been confirmed by a head-to-head interaction study; it follows from how alendronate's absorption is known to behave with food, minerals, and other oral agents generally.

What glutathione is and why people combine it with Fosamax

Glutathione is a tripeptide made from glycine, cysteine, and glutamate. It is the body's main intracellular antioxidant and supports Phase II liver detoxification through the glutathione S-transferase enzyme family. It is sold as oral capsules, liposomal formulations meant to improve absorption, and IV infusions given in clinical or wellness settings, and it overlaps with N-acetylcysteine (NAC), a precursor that raises intracellular cysteine.

People taking alendronate for osteoporosis are often older adults who also use antioxidant supplements for general wellness, skin, or liver-support reasons unrelated to bone health, which is why the two show up together on medication lists. Whether oral glutathione is well absorbed and produces a meaningful rise in blood glutathione levels has been studied in small trials, but the exact magnitude of benefit is not something this page can state with a specific number without verifying the primary study first.

Why alendronate's absorption is unusually fragile

Alendronate has one of the lowest oral bioavailabilities of any commonly prescribed drug, and the FDA-approved prescribing information for Fosamax instructs patients to take it first thing in the morning with plain water only, staying upright, and waiting at least 30 minutes before any food, beverage, or other medication. Coffee, juice, food, calcium, and other supplements taken close to the dose reduce absorption further, according to the same labeling. This is a class-wide bisphosphonate issue rather than something specific to alendronate.

The mechanism is chemical rather than pharmacological. Alendronate carries multiple negative charges at physiological pH and readily forms insoluble complexes with calcium, magnesium, iron, and other polyvalent cations in the gut. Anything that changes the pool of free cations or gastric acidity in the stomach around dosing time can worsen an already marginal absorption rate.

Does glutathione chemically interact with alendronate?

No published pharmacokinetic study directly testing simultaneous oral glutathione and alendronate in humans was identified for this page. That absence of data matters and should be stated plainly rather than papered over.

What is biologically plausible: glutathione's cysteine residue carries a free thiol group, and thiols are known to bind certain metals (copper, zinc, and others) in biochemistry generally. Alendronate itself is not a metal ion, so a direct chelation reaction between glutathione and alendronate is not the concern. A more indirect and unproven possibility is that oral glutathione could shift the pool of free minerals in the gut lumen around dosing time, marginally affecting alendronate's already unpredictable absorption. This is a mechanistic hypothesis, not an established finding.

What is not established: any pharmacodynamic antagonism between glutathione and bisphosphonate action on bone. Alendronate works by inhibiting an enzyme in the mevalonate pathway inside osteoclasts, causing osteoclast apoptosis after the drug binds to bone mineral. Oxidative stress is separately associated with osteoclast activity in observational research, which has led to speculation that antioxidants including glutathione could have a complementary or neutral effect on bone turnover. No trial has tested glutathione specifically for this purpose, and no study has reported that glutathione blocks or weakens bisphosphonate action.

Metabolic pathway: alendronate is not metabolized by the liver; it is excreted unchanged by the kidneys, according to its FDA labeling. This removes cytochrome P450 or hepatic Phase II enzyme interactions from consideration for this specific pair, even though glutathione does influence Phase II metabolism for other drugs.

IV or liposomal glutathione is a separate question

Patients who receive IV glutathione at infusion clinics sometimes schedule it on the same day as their weekly alendronate dose. This deserves separate caution, not because of chelation, but because IV glutathione produces a transient, much higher-than-normal thiol load in circulation, and alendronate is cleared renally over a period of days after dosing. Whether high circulating thiol levels could compete with bisphosphonate renal handling has not been studied. Scheduling IV glutathione on a different day from a weekly alendronate dose, with roughly 24 hours of separation, is a precaution based on absence of data rather than documented harm, and it should be discussed with the prescribing clinician.

Evidence-status assessment

The dominant, actionable concern across this table is oral absorption timing, which is fully within the patient's control.

A practical timing approach

For a patient on weekly 70 mg alendronate, one reasonable schedule is:

1. Take alendronate first thing in the morning with a full glass of plain water, and remain upright.
2. Take nothing else by mouth, including glutathione, for at least 30 minutes, per FDA labeling; many clinicians extend this to 60 minutes for supplements containing amino acids or minerals.
3. Wait a full two hours before taking oral or liposomal glutathione, as an added margin of safety given the lack of specific interaction data.
4. On days without alendronate dosing, glutathione may be taken at any time relative to meals.

This same two-hour separation is also a reasonable precaution for NAC, since it shares glutathione's free thiol group and metal-binding potential.

Monitoring if both have already been taken close together

A single instance of taking glutathione close to an alendronate dose is unlikely to cause harm, though it may have reduced that day's absorption. Do not take an extra alendronate dose to compensate; resume the normal schedule at the next dose.

For patients on long-term alendronate who want reassurance that therapy is working, clinicians commonly use bone turnover markers such as CTX (a marker of osteoclast activity) and periodic dual-energy X-ray absorptiometry (DXA) scanning to track treatment response. The NIH Osteoporosis and Related Bone Diseases National Resource Center is a reasonable starting reference for how bisphosphonate therapy is typically monitored, though specific thresholds and retesting intervals should come from the prescribing clinician rather than this page, since they depend on the individual's baseline values and risk factors.

Contact the prescribing clinician if:

• Oral glutathione has consistently been taken within 30 minutes of alendronate for an extended period
• Bone density testing shows no improvement or unexpected loss on repeat DXA
• A fracture occurs while on therapy, or unexplained height loss is noticed

Special situations

Postmenopausal women, who make up most alendronate users, often also take calcium and vitamin D as adjuncts to bisphosphonate therapy. Calcium supplements require the same absorption-timing separation from alendronate as any other oral agent, and this is a more clearly documented interaction than the glutathione question.

Chronic kidney disease: alendronate is contraindicated in patients with significantly reduced creatinine clearance, per its FDA labeling. Patients with reduced kidney function who also receive IV glutathione should have explicit coordination between their care team before combining the two, since renal handling of both is a relevant shared pathway even though it has not been directly studied.

Evidence boundary

Established: alendronate has very low, easily disrupted oral bioavailability, and its FDA label instructs strict fasting-morning dosing with plain water and a delay before any food, beverage, or other oral medication. Alendronate is renally cleared and not hepatically metabolized.

Plausible but unproven: that oral glutathione's thiol chemistry could have a small indirect effect on alendronate absorption through gut mineral availability; that glutathione's antioxidant effects could be complementary to, rather than competing with, bisphosphonate action on bone.

Not established: any direct chelation between glutathione and alendronate, any pharmacodynamic antagonism affecting bone density outcomes, and any documented effect of high-dose IV glutathione on alendronate renal clearance. No trial has tested this specific combination in humans, and general reassurance about safety should be read with that gap in mind.

This article does not provide individualized dosing advice. Anyone on alendronate who takes or is considering glutathione, in any form, should discuss their full supplement list with their prescriber or pharmacist, particularly if kidney function is reduced or if IV glutathione infusions are planned.